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a b s t r a c t
Introduction: The objective of this study is to evaluate the insulin secretion of mixed aggregates of
insulinoma cells (INS-1) and gelatin hydrogel microspheres after their subcutaneous transplantation.
Methods: Gelatin hydrogel microspheres were prepared by the conventional w/o emulsion method. Cell
aggregates mixed with or without the hydrogel microspheres were encapsulated into a pouched-device
of polytetraﬂuoroethylene membrane. An agarose hydrogel or MedGel™ incorporating basic ﬁbroblast
growth factor (bFGF) was subcutaneously implanted to induce vascularization. After the vascularization
induction, cell aggregates encapsulated in the pouched-device was transplanted.
Results: The vascularization had the potential to enable transplanted cell aggregates to enhance the level
of insulin secretion compared with those of no vascularization induction. In addition, the insulin
secretion of cell aggregates was signiﬁcantly promoted by the mixing of gelatin hydrogel microspheres
even in the pouched-device encapsulated state.
Conclusion: It is possible that the microspheres mixing gives cells in aggregates better survival condition,
resulting in promoted insulin secretion.
© 2018, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
Islet transplantation is one option of type I diabetes therapies
[1e3], but many patients can hardly receive the medical treatment
because of the serious donor shortage [4e6]. Islet-like cell aggre-
gates formed artiﬁcially from pancreatic b cells may be potential to
overcome this issue [7,8]. However, when the cell aggregates
become large over 200 mm in diameter, cells inside the cell aggre-
gates are susceptible to necrosis because of the lack of oxygen and
nutrient supplies [9,10]. It is well recognized that b cells are
generally sensitive to a hypoxic environment and need a large
amount of oxygen to secrete insulin [11,12]. Therefore, it is
indispensable for a high cell viability and function like glucose-
induced insulin secretion (GIIS) to improve the condition of oxy-
gen and nutrient supplies to cells inside cell aggregates. We
demonstrate that the mixing of gelatin hydrogel microspheres
enabled mesenchymal stem cells in their aggregates to improve the
cell viability, proliferation, and osteogenic differentiation [13,14].
This is mainly because the microspheres promoted the oxygen and
nutrients supply to cells inside. This mixing technology with
hydrogel microspheres will be effective in improving b cell viability
and the functions in cell aggregates.
For the site of b cells transplantation, the subcutaneous (SC)
tissue is preferable because it is easy to transplant cells and remove
the cells transplanted if some problems happen [15e17]. However,
one of the big difﬁculties is to maintain the cell viability at the SC
site because blood vessel networks are poor to allow cells to survive
thereat. Generally, as one trial to breakthrough the problem,
vascularization around the transplantation area has been tried to
induce by several methods [15e20]. However, an appropriate
vascularization timing remains to be fully elucidated.
In this study, gelatin hydrogel microspheres were mixed in the
aggregates of insulinoma cells (INS-1) as a model b cell [21] to
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expect the pathway creation of oxygen and nutrients in aggregates
to evaluate whether or not the hydrogel microspheres mixing
modiﬁes the function of cell aggregates in vitro and in vivo. INS-
1 cell aggregates mixed with or without gelatin hydrogel micro-
spheres were encapsulated into a pouched-device and subcutane-
ously transplanted into the back of rats. Before the transplantation,
vascularization by basic ﬁbroblast growth factor (bFGF) was
induced to assess the effect of vascularization on the insulin
secretion from the cell aggregates encapsulated in the device
transplanted.
2. Materials and methods
2.1. Preparation of gelatin hydrogel microspheres
Gelatin hydrogel microspheres were prepared by the chemical
cross-linking of gelatin in awater-in-oil emulsion state according to
the method previously reported [13]. Brieﬂy, an aqueous solution
(20 ml) of 10 wt% gelatin (isoelectric point 5.0, weight-averaged
molecular weightx1,00,000, Nitta Gelatin Inc., Osaka, Japan) was
preheated at 40 C, and then added dropwise into 600 ml of olive
oil (Wako Pure Chemical Industries Ltd., Osaka, Japan) at 40 C,
followed by stirring at 200 rpm. for 10min to prepare awater-in-oil
emulsion. The emulsion temperature was decreased to 4 C for the
natural gelation of gelatin solution to obtain non-crosslinked mi-
crospheres. The resulting microspheres were washed three times
with cold acetone in combination with centrifugation (5000 rpm.,
4 C, 5 min) to completely exclude the residual oil. Then they were
fractionated by size using sieves with apertures of 32 and 53 mm
(Iida Seisakusyo Ltd., Osaka, Japan) and air dried at 4 C. The non-
crosslinked and dried gelatin microspheres (200 mg) were
treated in a vacuum oven at 140 C and 0.1 Torr for 48 h for the
dehydrothermal crosslinking of gelatin. Pictures of gelatin hydrogel
microspheres in a dispersed state in RPMImedium 1640 containing
L-glutamine (Invitrogen ltd., Carlsbad, CA) were taken with a light
microscope (BZ-X710, KEYENCE Corp., Osaka, Japan). The size of
100 microspheres for each sample was measured using the com-
puter program of microscope (BZ-X710) to calculate the average
diameter.
2.2. Preparation of INS-1 cell aggregates with or without gelatin
hydrogel microspheres and insulin secretion evaluation (GIIS assay)
The cell line 832/13, derived from INS-1 rat insulinoma cells,
was obtained from Dr. Christopher B. Newgard (Duke University
Medical Center, Durham, NC) [21]. Cells were grown in RPMI me-
dium 1640 containing L-glutamine (Invitrogen Ltd.), 1 mM sodium
pyruvate (Invitrogen Ltd.), 10 mM HEPES (Invitrogen Ltd.), 10 vol%
heat-inactivated fetal bovine serum (Thermo Fisher Scientiﬁc Inc.,
Waltham, MA), 55 mM 2-mercaptoethanol (Invitrogen Ltd.), 100 IU/
ml penicillin (Gibco, Grand Island, NY), and 100 mg/ml streptomycin
(Gibco). Cells were cultured in a humidiﬁed atmosphere containing
5% CO2/95% air at 37 C.
Gelatin hydrogel microspheres and INS-1 cells were separately
suspended in the culture medium. The initial seeding density of
cells was 1  103 or 1  104 cells/well at the cells/microspheres
number ratio of 100/1. The mixed suspensions of microspheres and
INS cells (14 ml) were added to EZSPHERE (4000-905, AGC Techno
Glass Co. Ltd., Shizuoka, Japan). Pictures of INS-1 cell aggregates
with or without the gelatin hydrogel microspheres incorporation
were taken with the microscope as described above.
Cell aggregates with or without gelatin hydrogel microspheres
were transferred to each well of a 12 mm Transwell (#3402, Coring
Inc. Corning, NY) and washed once by phosphate-buffered saline
solution (PBS, Gibco). Then, Krebs-Ringer-bicarbonate HEPES (KRB)
buffer solution containing 10 mM glucose [21] was added to each
well, and the cell aggregates were incubated for 1 h at 37 C. The
concentration of insulin secreted in the supernatants was
measured by ELISA kit (Rat Insulin ELISA KIT, Shibayagi Co. Ltd.,
Gunma, Japan). Experiments were performed on three wells for
each sample.
2.3. SC vascularization induction with bFGF
Male Wistar rats were purchased from Charles River Labora-
tories Japan, Inc. (Yokohama, Japan). The care and use of the ani-
mals and the experimental protocols used in this research were
approved by the Experimental Animal Care and Use Committee of
Takeda Pharmaceutical Company Limited.
An agarose hydrogel was prepared [22]. Brieﬂy, 4.5 wt%
agarose (SeaKem GTG Agarose; Camrex Bio Science Rockland, Inc.,
Rockland, ME) solution in water was prepared by autoclave, fol-
lowed by the solution cooling to 25 C for the natural gelation.
Next, the hydrogel was freeze-dried to obtain the agarose
hydrogel. The agarose hydrogel was formulated into a round
shape (3.0 cm in diameter) or an oval shape with 1.5  3.0 cm, and
then covered by a polyvinylidene diﬂuoride membrane (PVDF) to
suppress the adhesion to the surrounding subcutaneous tissues
[23]. bFGF (500 mg of Fiblast Spray, Kaken Parmaceutical Co., Ltd.,
Tokyo, Japan) was dissolved in 500 ml of PBS. The bFGF solution
(50 ml) was dropped onto the dried agarose hydrogel, following
leaving at 25 C for 30 min to prepare the agarose hydrogel con-
taining 50 mg of bFGF. The agarose hydrogel containing bFGF was
implanted into the back subcutis of rats. The hydrogel was taken
out 7 days later to visually observe the induction of vasculariza-
tion around the implanted site. As another material, a gelatin
hydrogel (0.5  0.5 cm, pI 5, MedGel, Tokyo, Japan) was used to
induce the vascularization in vivo. Similarly, 50 mg of bFGF was
impregnated into the gelatin hydrogel. The gelatin hydrogel
containing bFGF was implanted to induce vascularization for 7
days.
2.4. In vitro evaluation of insulin secretion for cell aggregates
encapsulated in the pouched-device after in vivo transplantation
(GIIS assay)
Several in vivo experiments were performed to evaluate the
effect of vascularization and gelatin hydrogel microspheres mixing
on the insulin secretion for cell aggregates encapsulated in the
pouched-device (Scheme 1). To retain the cell aggregates at the
transplanted site, a pouched-device was made of polytetraﬂuoro-
ethylene membrane (PTFE) (Omnipore Membrane Filter, Hydro-
philic, 0.45 mm, Millipore Corp., Bedford, MA), which is a
biocompatible material clinically available [24]. The 2 PTFE mem-
branes were adhered by a heat-adhesion with a ring-shaped
polypropylene membrane (Preﬁlter, Hydrophobic, 0.6 mm pore,
Millipore Corp., Bedford, MA). A tube (1.5 mm in inner diameter, PE
Tubing, Natsume Manufacturing, Tokyo) was inserted into the
pouched-device (Scheme 1a). The cell aggregates without gelatin
hydrogel microspheres were infused into the pouched-device by
insertion of an 18 G needle (TERUMO Corp., Tokyo, Japan) (750 cell
aggregates/pouched-device). Then, they were subcutaneously
transplanted into the SC site of rats which the vascularization
treatment had been performed with bFGF containing the agarose
hydrogel (Group 1) or had not been done (Group 2). The pouched-
device was taken out 3 days later and the glucose-KRB solutionwas
added to the pouched-device, followed by incubation for 2 h at
37 C. Experiments were performed for six mice. Similarly, the
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pouched-device containing cell aggregates with or without (Group
3) gelatin hydrogel microspheres was subcutaneously transplanted
after vascularization treatment for 7 days and the insulin concen-
tration in the supernatant was measured. Experiments were per-
formed for four mice.
2.5. Statistical analysis
All the statistical data are expressed as mean ± standard error of
the mean (SEM). The data were analyzed using the Student's t-test
and the statistical signiﬁcance was accepted at P < 0.05 or 0.01.
Scheme 1. (a) A schematic illustration of a pouched-device to encapsulate cell aggregates. Two PTFE membranes were adhered by a heat-adhesion with a ring-shaped PP
membrane. (b) A picture of agarose hydrogel covered by a PVDF membrane. (c) A picture of gelatin hydrogel (MedGel™). (d) Experimental schedule to evaluate the insulin
secretion of implanted cell aggregates in the pouched-device: Group1, an agarose hydrogel was implanted to induce vascularization for the initial vascularization for the initial
7 days. After the hydrogel was removed, cell aggregates encapsulated in the pouched-device were transplanted. Cell aggregates were taken out 3 days later and their insulin
secretion was evaluated. Group 2, without any vascularization treatment, cell aggregates encapsulated in the pouched-device were transplanted. Cell aggregates were taken
out 3 days later and their insulin secretion was evaluated. Group 3, a gelatin hydrogel (MedGel™) was implanted to induce vascularization for the initial 7 days. After the
hydrogel was removed, cell aggregates encapsulated in the pouched-device were transplanted. Cell aggregates were takenout 3 or 7 days later and their insulin secretion was
evaluated.
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3. Result
3.1. Characterization of gelatin hydrogel microspheres
Fig. 1 shows the typical microscopic pictures of gelatin hydrogel
microspheres. The microspheres were of spherical shape and had a
smooth surface. The microspheres could be fractionized in size by
using the sieve.
3.2. Characterization of INS-1 cell aggregates with or without
gelatin hydrogel microspheres and insulin secretion in vitro
Fig. 2 shows the microscopic pictures of cell aggregates with
or without gelatin hydrogel microspheres 5 or 7 days after cell
culture. Cell aggregates without gelatin hydrogel microspheres
were obtained at any initial seeding density. When the initial
seeding density was 1  104 cells/well, cell aggregates uniformly
containing gelatin hydrogel microspheres were not formed. The
gelatin hydrogel microspheres were located at the centre of a cell
aggregate. On the other hand, the cell aggregates uniformly
containing gelatin hydrogel microspheres were successfully
formed at the initial seeding density of 1  103 cells/well.
Therefore, based on this, 1  103 cells/well of the initial seeding
density was used for the following experiment. The formation
speed of cell aggregates with gelatin hydrogel microspheres of
47.0 mm in diameter of was higher compared with that of cell
aggregates containing hydrogel microspheres of 91.0 mm in
diameter.
Fig. 3 shows the insulin secretion of INS-1 cell aggregates 7 days
incubation with or without gelatin hydrogel microspheres. Cell
aggregates with gelatin hydrogel microspheres of 91.0 mm in
diameter secreted signiﬁcantly larger amount of insulin than those
without the gelatin microspheres or with the microspheres of
47.0 mm in diameter. The following experiment was performed by
using the gelatin hydrogel microspheres of 91.0 mm in diameter
unless otherwise mentioned.
Fig. 1. Light microscopic pictures of gelatin hydrogel microspheres dispersed in the culture medium. The diameter of gelatin hydrogel microspheres is (a) 47.0 ± 11.0 or (b)
91.0 ± 19.0 mm. Scale bar is 100 mm.
Fig. 2. Light microscopic pictures of INS-1 cell aggregate 5 (a, b, c) and 7 days (d, e, f) after incubation with or without gelatin microspheres. INS-1 cell aggregates were cultured with
gelatin hydrogel microspheres of 47.0 mm (b, e) and 91.0 mm in diameter (c, f) or without gelatin microspheres (a, d). The numbers of cells initially added are 1  104 and 1  103 for
47.0 mm and 91.0 mm diameter microspheres, respectively. Scale bar is 200 mm. Arrows indicate gelatin hydrogel microspheres.
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3.3. Effect of vascularization on insulin secretion of cell aggregates
Fig. 4 shows that tissue appearance 7 days after implantation of
an agarose hydrogel without bFGF (a) or containing 50 mg of bFGF
(b) into the back subcutis of rats. (c) Tissue appearance of normal
rat. Vascularizationwas successfully induced by the implantation of
agarose hydrogels containing bFGF. Less vascularization was seen
for bFGF-free agarose hydrogel.
Fig. 5 shows that insulin secretion of INS-1 cell aggregates
encapsulated in the pouched-device with or without 3 days
vascularization by the agarose hydrogel implantation. Cell aggre-
gates transplanted into the site which had been vascularized by the
implantation of agarose hydrogel containing bFGF (Group 1)
showed the tendency of higher than amount of insulin secretion
compared with those transplanted into non-vascularized site
(Group 2), although the was no signiﬁcant difference. The potential
that vascularization treatment enables the cell aggregates to
enhance the amount of secreted insulin secreted.
3.4. Effect of gelatin hydrogel microspheres mixing and
vascularization timing on insulin secretion cell aggregates in vivo
Fig. 6 shows that insulin secretion of INS-1 cell aggregates with
or without gelatin hydrogel microspheres encapsulated in the
pouched-device before SC transplantation, and 3 and 7 days
transplantation. Cell aggregates with gelatin hydrogel micro-
spheres in the pouched-device secreted the amount of insulin to a
signiﬁcant higher extent than those without gelatin hydrogel mi-
crospheres mixing 3 and 7 days after transplantation. The amount
of secreted insulin decreased compared with that before trans-
plantation. However, there was no signiﬁcant difference in the in-
sulin secretion between 3 and 7 days after transplantation.
4. Discussion
Generally, multi-well U or V-bottomed plates or the hanging-
drop method are used to prepare cell aggregates in lab-scale
[25e27]. However, in this study, the EZSPHERE was selected
considering the large-scale preparation of cell aggregates aiming at
their transplantation [28,29]. The EZSPHERE was effective in
forming cell aggregates with or without the gelatin hydrogel mi-
crospheres mixing of cell aggregates. The mixing of gelatin hydro-
gel microspheres signiﬁcantly promoted the insulin secretion of
cell aggregates (Fig. 3). The formation of cell aggregates was
inﬂuenced by the initial seeding density of cells. At the initial
seeding density of 1 104 cells/well, gelatin hydrogel microspheres
Fig. 3. Insulin secretion of INS-1 cell aggregates 7 days incubation with or without
gelatin hydrogel microspheres. *P < 0.01: signiﬁcant different between the groups.
yP < 0.01: signiﬁcant different between the groups.
Fig. 4. Tissue appearance 7 days after implantation of an agarose hydrogel without
bFGF (a) or containing 50 mg of bFGF (b) into the back subcutis of rats. (c) Tissue
appearance of normal rat.
Fig. 5. Insulin secretion of INS-1 cell aggregates encapsulated in the pouched-device
without or with 3 days vascularization by the agarose hydrogel implantation. Vascu-
larization (þ) or () respectively shows the group with or without vascularization
before transplantation.
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were located at the bottom of wells while cells proliferated around
them, which caused no formation of cell aggregates mixed with
microspheres. It is likely that heavier microspheres sunk down to
the well bottom faster than cells, and consequently placed the well
surface. In addition, the well size of EZSPHERE would be too small
to form cell aggregates (diameter; 1400 mm, depth; 600 mm)
because microspheres occupied the well. On the other hand, cell
aggregates were successfully formed at the initial seeding density
of 1  103 cells/well, and an uniform distribution of cells and mi-
crospheres was observed in the cell aggregates. The in vitro insulin
secretion assay revealed that at 1 103 cells/well, themicrospheres
mixing improved the insulin secretion from cell aggregates, and the
improvement was signiﬁcantly higher for larger microspheres than
smaller microspheres. The same result was obtained in preparing
cell aggregates with the gelatin microspheres in 96 well V-
bottomed plates. We can say that the microspheres of larger vol-
ume were more efﬁcient to create the pathway of oxygen and nu-
trients supply to cells inside the cell aggregates than smaller
microspheres. This is because oxygen and nutrients are generally
permeated through the water phase of homogeneously mixing
hydrogels.
Although we have no data on the maturity and amount of blood
vessels, we believe that it is apparent that bFGF incorporation
promoted vascularization in vivo to a signiﬁcantly great extent
compared with no incorporation from Fig. 4. The vascularization
ability of bFGF was known well and there have been reported on
the bFGF-induced vascularization [30e32]. However, less vascu-
larization for bFGF-free hydrogel was induced. This may be due to
the hydrogel property to induce inﬂammation. To assess the
inﬂammation caused by agarose hydrogels, agarose hydrogels
containing bFGF with different sizes were subcutaneously
implanted. When the tissue was evaluated 1 week after the im-
plantation, larger hydrogels induced severe edemas. As the size of
hydrogels decreased, the edema tended to reduce (Supplemental
Fig. 1 bed). Based on this, in this study, the agarose hydrogel of
1.5  3.0 cm was selected for vascularization induction to evaluate
the effect of vascularization on the insulin secretion in vivo.
Considering the clinical treatment of diabetes by cell trans-
plantation, it is desired to suppress the inﬂammation caused by the
transplantation and in addition, simplify the transplantation pro-
tocol. The gelatin hydrogel is degraded with time in vivo [30,31].
Therefore, the hydrogels are not required to be removed after
vascularization. We experimentally demonstrated that gelatin
hydrogels were degraded about 1 week after the SC implantation.
To reduce inﬂammation, the smaller size (0.5  0.5 cm) to incor-
porate bFGF solution was selected for the following in vivo study
(Supplemental Fig. 1a).
Cell aggregates transplanted into the site which had been vas-
cularized by the implantation of agarose hydrogel containing bFGF,
showed high amount of secreted insulin compared with those
transplanted into non-vascularized site, although there was no
signiﬁcant difference (Fig. 5). This may be due to the large ﬂuctu-
ation of experimental values. However, this ﬁnding strongly sug-
gests that the vascularization induction was required to maintain
the function of cell transplantation. When calculated per one
aggregate without gelatin hydrogel microspheres, the amount of
insulin secretion even after vascularization remained only around
1/50 comparing with that before transplantation. There are various
reasons for this phenomenon. Firstly, low oxygen tension in the site
to be transplanted deteriorates the condition of cells. Secondly, the
viability of cell aggregates was lost when encapsulated into the
pouched-device, because the oxygen permeability of PTFE mem-
brane is limited. In addition, an absorption test demonstrates that
the insulin absorption to the PTFE membrane was detected (data
not shown). As one trial to tackle the absorption, it is necessary to
optimize the materials for the pouched-device in terms of low
absorption property and high biocompatibility [33e35]. It is re-
ported that the pouched-devices have a property to induce
vascularization in the transplantation site [35e37]. Base on them,
the PTFE membrane was used in the present study. In addition, to
suppress the crumping of encapsulated cell aggregates in the
pouched-device and uniformly distribute oxygen to the aggregates
in the device, the inner shape of the device and the cell encapsu-
lation method should be modiﬁed [38e40]. Because the uniform
distribution of cell aggregates would supply a good survival con-
dition to aggregates in the pouched-device. If the cell aggregates
are heterogeneously located in the device, even if the vasculariza-
tion around the device is induced, the blood supply to cells is not
sufﬁcient for their survival. Therefore, the method of SC vasculari-
zation should be optimized for the SC transplantation. In addition,
it is necessary to develop other strategies for improved blood
supply for cells by making use of chemical compound [41], bio-
logical protein [42], and mechanical device [43]. There have been
reported on other technologies studied to overcome this cell
function decrease. One of the technologies is to use a hydrogel in
which cells are embedded as the transplantation substrate
[44e46]. Matrigel is the most famous hydrogel for cell trans-
plantation [47,48]. Although Matrigel improves the retention rate
and viability of transplanted cells, Matrigel is a solubilized base-
ment membrane extracted from Engelbreth-Holm-Swarm (EHS)
mouse sarcoma, and it is difﬁcult to apply for the clinical study.
Furthermore, it is highly conceivable that the presence of hydrogels
suppresses the biological response of glucose-induced insulin
secretion because glucose and insulin have to diffuse in hydrogels.
To overcome this problem on the diffusion of biological factors, the
conformal coating method was developed, which utilized the
chemical crosslinking on the surface of cell aggregates [49,50].
However, this chemical crosslinking reaction and crosslinking
agents sometimes decrease the cell viability. On the other hand,
our microspheres enable biological factors to interact with
cells directly, and the technology does not cause the chemical
damage.
Fig. 6. Insulin secretion of INS-1 cell aggregates with (black bars) or without gelatin
hydrogel microspheres (white bars) encapsulated in the pouched-device before SC
transplantation, and 3 and 7 days transplantation. Cell aggregates were subcutane-
ously transplanted after the vascularization for 7 days.
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Cell aggregates with large gelatin hydrogel microspheres in
the pouched-device secreted a signiﬁcantly higher amount of
insulin than those without microspheres mixing. This technology
was experimentally conﬁrmed both for the in vitro and in vivo
systems (Fig. 6). However, the amount of insulin secretion from
cell aggregates decreased after their transplantation when
compared with that of in vitro culture condition. This can be
explained in terms of oxygen tension. It is conceivable that in the
subcutaneous site, the oxygen concentration is not high enough
to maintain the survival and function retention of cells externally
transplanted. To break through the low oxygen concentration at
the site to be transplanted, it is of prime importance to design
and develop the material and structure of devices for cell ag-
gregates encapsulation. The vascularization method should be
also modiﬁed to allow the transplanted cell aggregates to supply
oxygen. There was no signiﬁcant difference in the level of insulin
secretion between 3 and 7 days post-transplantation. This sug-
gests that the oxygen supply by the vascularization treatment
was efﬁcient to maintain the function of cell aggregates. How-
ever, a longer-term evaluation should be performed in the future.
To optimize the timing of vascularization, the gelatin hydrogel
containing bFGF was subcutaneously implanted at the same or
different time of cell transplantation. The pouched-device con-
taining cell aggregates with or without gelatin hydrogel micro-
spheres was transplanted into the subcutaneous site of rat after
vascularization (Group 3) or at the same time as cell trans-
plantation (Group 4) (Supplemental Fig. 2). There was no dif-
ference between Group 3 and 4 after 3 or 7 days transplantation.
It has been demonstrated that the bFGF release initiated imme-
diately after implantation, resulting in the subsequent generation
of bFGF-induced vascularization [30,31]. The similar result was
obtained by the spontaneous implantation of the gelatin
hydrogel with the cell aggregates. This ﬁnding indicates that the
removal of vascularization device for the subsequent cell trans-
plantation is not required.
The present study demonstrates that the vascularization or the
mixing with gelatin hydrogel microspheres and the microspheres
size affect the behavior of insulin secretion for cell aggregates. The
technology of hydrogel microspheres mixing and vascularization
treatment is promising to achieve the cost reduction and high
therapeutic effect in cell transplantation therapy. Since the pur-
pose of this study was to show the potential of gelatin hydrogel
microspheres to improve the insulin secretion in vivo, we did not
perform in vivo study using a diabetes model animal and the
measurement of blood glucose levels. It is demonstrated that
vascularization development with growth factors like bFGF, is
known to be impaired in diabetes models [51e53]. It is easily easy
to imagine the phenomenon that the transplanted cells are
exposed to a harsher environment in diabetes models. Therefore,
we strongly believe that the present microspheres improve elicit
the effect on insulin secretion improvement in vivo. In the future,
we plan to evaluate not only the insulin secretion in vivo from cell
aggregates with or without microspheres, but also the blood
glucose level.
5. Conclusions
The vascularization induced by bFGF release enabled trans-
planted cell aggregates to enhance the level of insulin secretion
compared with no vascularization induction. In addition, the in-
sulin secretion of cell aggregates was signiﬁcantly promoted by the
mixing of gelatin hydrogel microspheres both in vitro and vivo
systems. It is concluded that the microspheres mixing had the
potential to give cells in aggregates a better survival condition,
resulting in the promoted insulin secretion.
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